Sigma delivers 20.6% earnings growth with Normalised EBIT at $1.09 billion

Sigma Healthcare Limited (Sigma) today announces its results for the full year ended 30 June 2026 (FY26) – its first full financial year following the merger with the Chemist Warehouse Group (CWG). The result delivers double-digit revenue and earnings growth, continued network expansion across domestic and international markets, and disciplined progress on integration and synergy delivery.

FY26 Financial Highlights ¹

• Revenue of $10.8 billion, up 15.5%
• Normalised EBIT of $1,090.0 million, up 20.6%, with Normalised EBIT margin up to 10.1%
• Normalised NPAT of $732.3 million, up 22.3%
• Net debt reduced to $663 million with Debt to Normalised EBITDA ratio at 0.57x, reflecting a strong and conservatively leveraged balance sheet
• $32.6 million of integration synergies delivered, and on track to reach $100 million per annum by FY29
• Australian segment delivers 14.9% revenue growth and 18.3% growth in Normalised EBIT
• International segment EBIT up 91.3% to $55.8 million, as growth accelerates and Ireland becomes profitable for the first time.

• View the accompanying documentation

Read the full ASX release

View the FY26 results presentation

Appendix 4G

Dividend / Distribution

1. [1] All Sigma financial prior corresponding period comparisons are a reference to Normalised Pro-forma FY25. ↩︎